281 related articles for article (PubMed ID: 28304139)
1. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
[TBL] [Abstract][Full Text] [Related]
2. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
[TBL] [Abstract][Full Text] [Related]
4. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
[TBL] [Abstract][Full Text] [Related]
5. The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.
Xing P; Zhu Y; Shan L; Chen S; Hao X; Li J
Oncotarget; 2017 Oct; 8(50):87442-87454. PubMed ID: 29152093
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Martín M; Chacón JI; Antón A; Plazaola A; García-Martínez E; Seguí MA; Sánchez-Rovira P; Palacios J; Calvo L; Esteban C; Espinosa E; Barnadas A; Batista N; Guerrero A; Muñoz M; Romio E; Rodríguez-Martín C; Caballero R; Casas MI; Rojo F; Carrasco E; Antolín S
Oncologist; 2017 Nov; 22(11):1301-1308. PubMed ID: 28701571
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
Kotake M; Kuwako T; Imai H; Tomizawa Y; Kaira K; Yoshii A; Ochiai M; Miura Y; Osaki T; Sakurai R; Takei K; Minato K; Saito R
Chemotherapy; 2020; 65(1-2):21-28. PubMed ID: 32674095
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer.
Yang M; Qu H; Liu A; Liu J; Sun P; Li H
J Cancer Res Ther; 2019; 15(7):1561-1566. PubMed ID: 31939438
[TBL] [Abstract][Full Text] [Related]
11. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H
Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912
[TBL] [Abstract][Full Text] [Related]
13. A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
Tanaka H; Taima K; Morimoto T; Tanaka Y; Itoga M; Nakamura K; Hayashi A; Kumagai M; Yasugahira H; Mikuniya M; Okudera K; Takanashi S; Tasaka S
BMC Cancer; 2017 Oct; 17(1):683. PubMed ID: 29037236
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
Xiong W; Xu T; Liu X; Zhang L; Yuan Y
Cancer; 2024 Apr; 130(S8):1488-1498. PubMed ID: 38271397
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis.
Tan H; Hu J; Liu S
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):268-277. PubMed ID: 30600739
[TBL] [Abstract][Full Text] [Related]
17. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
[TBL] [Abstract][Full Text] [Related]
18. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
Blair HA; Deeks ED
Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
